Hypoglycaemia (revision 1)
Old revision·18:02, 6 Aug 2024·CrudePeptidePearl
This is an old revision of this page, as it stood at 18:02, 6 Aug 2024, saved by CrudePeptidePearl with the summary create article — adverse-effect stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Hypoglycaemia | |
|---|---|
| Common threshold | Below 3.9 mmol/L (70 mg/dL) |
| Level 2 | Below 3.0 mmol/L (54 mg/dL) |
| Level 3 | Severe: requires assistance |
| Risk with incretin monotherapy | Low |
| Topic infobox · conventions | |
Hypoglycaemia is abnormally low blood glucose. It is classified by level: below 3.9 mmol/L as an alert value, below 3.0 mmol/L as clinically significant, and any episode requiring assistance as severe regardless of the measured value.[1]
Incretin agonists carry a low intrinsic risk because their action on insulin secretion is glucose-dependent: they amplify a response that glucose has initiated rather than initiating one. Below the glucose threshold for triggering, there is nothing to amplify.[2]
References
Categories: